|
Luminal B Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We further sub-classified LH into patients with carcinomas expressing high levels of hormone receptors (LH-high; Allred score, oestrogen receptor [ER] and/or progesterone receptor [PgR] 4-8) (n=89 [53.6%]) or low levels (LH-low; Allred score, ER and/or PgR 2 or 3) (n=21 [12.7%]) for clinicohistomorphological characterization.
|
31554015 |
2020 |
|
Luminal B Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We investigated parity, breastfeeding, and breast cancer risk by hormone-receptor (estrogen (ER) and progesterone receptor (PR)) and molecular subtypes (luminal A, luminal B, HER2-enriched, and basal-like) in the Nurses' Health Study (NHS; 1976-2012) and NHSII (1989-2013).
|
30867002 |
2019 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We classified breast cancer cases into four subtypes using information on tumor marker expression such as estrogen receptor (ER), progesterone receptor (PR), and Cerb2 receptor (HER2); luminal A (ER+ and/or PR+, HER2-), luminal B (ER+ and/or PR+, HER2+), HER2-overexpressing (ER-, PR-, and HER2+), and triple-negative (ER-, PR-, and HER2-).
|
28957821 |
2018 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aims of the current study were (1) to analyze invasive breast carcinomas using standardized 4-IHC and quantitative image analysis and (2) to compare the results obtained in the classification of biological subtypes using current Ki67 and PR threshold values proposed by different authors to sub-classifying the luminal A-like and the luminal B-like (HER2-negative) subtypes.
|
28825136 |
2018 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumors were classified into molecular subtypes: luminal A (ER-positive and/or progesterone receptor (PR)-positive, human epidermal growth factor receptor type 2 (HER2) -negative, proliferation marker Ki-67 < 20 and low grade (I)) and luminal B (ER-positive and/or PR-positive, HER2-positive or HER2-negative with high Ki-67 ≥ 20 and higher grade (II or III)).
|
29284425 |
2017 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consistent with our finding that activated phospho-PRs undergo rapid ligand-dependent turnover, unique phospho-PR gene signatures were most prevalent in breast tumors clinically designated as PR-low to PR-null (luminal B) and included gene sets associated with cancer stem cell biology (HER2, PAX2, AHR, AR, RUNX).
|
28412963 |
2017 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Subtypes were defined as luminal A [estrogen receptor (ER)+ and/or progesterone receptor (PR)+, human epidermal growth factor receptor 2 (HER2)-, and Ki67 low], luminal B (HER2-) (ER+ and/or PR+, HER2-, and Ki67 high), luminal B (HER2+) (ER+ and/or PR+ and HER2+), HER2 overexpressing (ER-, PR-, and HER2+), and triple negative (ER-, PR-, and HER2-).
|
28409323 |
2017 |
|
Luminal B Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Determination of PgR expression combined with that of Ki-67 could thus improve the accuracy of IHC-based classification of luminal A and luminal B breast cancer, especially for postmenopausal women.
|
25600243 |
2015 |
|
Luminal B Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally we demonstrated a strong positive correlation between Rictor and PgR expression and a negative correlation with Raptor expression in Luminal B breast cancer samples, a breast cancer histological subtype known for having an altered ERα-signaling pathway.
|
25283550 |
2014 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently it has been shown that immunohistochemistry (IHC) markers including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her2), can divide tumors to main subtypes: luminal A (ER+; PR+/-; HER-2-), luminal B (ER+;PR+/-; HER-2+), basal-like (ER-;PR-;HER2-) and Her2+ (ER-; PR-; HER-2+).
|
23098526 |
2012 |
|
Luminal B Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Luminal A tumors more frequently expressed PR than Luminal B (94% vs 74%) and Luminal A tumors were less likely to have high proliferation (11% vs 77%).
|
23035882 |
2012 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cancers were categorized as luminal A (ER-alpha+ and/or PR+ and HER2-); luminal B (ER-alpha+ and/or PR+ and HER2+); HER2 (ER-alpha- and PR- and HER2+); and basal-like (ER-alpha-, PR-, HER2- and EGFR or cytokeratin 5/6+).
|
19898422 |
2010 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The invasive breast carcinomas were classified using semiquantitative immunohistochemical results for estrogen receptor (ER), progesterone receptor, (PR), and HER2 into following classes: Luminal A (strong ER+, HER2 negative), Luminal B (weak to moderate ER/PR+, HER2 negative), Triple Negative (TN; ER/PR negative, HER2 negative), ERBB2 (ER/PR negative, HER2 positive), Luminal A-HER2 Hybrid (strong ER+, HER2 positive), Luminal B-HER2 Hybrid (weak to moderate ER/PR+, HER2 positive).
|
19801938 |
2010 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Molecular subtypes were defined as luminal A [estrogen receptor (ER) positive and/or progesterone receptor (PR) positive, HER2-], luminal B (ER+ and/or PR+, HER2+), basal-like (ER-, PR-, HER2-, cytokeratin 5+, and/or HER1+), HER2+/ER- (ER-, PR-, and HER2+), and unclassified.
|
18593987 |
2008 |